Abstract. Dramatic improvements in the understanding of oncogenes have spurred the development of molecular target therapies, which created an exigent need for comprehensive and rapid clinical genotyping. Next-generation sequencing (NGS) assay with increased performance and decreased cost is becoming more widely used in clinical diagnosis. However, the optimization and validation of NGS assay remain a challenge, especially for the detection of somatic variants at low mutant allele fraction (MAF). In the present study, we developed and validated the Novogene Comprehensive Panel (NCP) based on targeted capture for NGS analysis. Due to the high correlation between SNV/INDEL detection performance and target coverage, here we focused on these two types of variants for our deep sequencing strategy. To validate the capability of NCP in single-nucleotide variant (SNV) and small insert and deletion (INDEL) detection, we implemented a practical validation strategy with pooled cell lines, deep sequencing of pooled samples (>2000X average unique coverage across target region) achieving >99% sensitivity and high specificity (positive predictive value, PPV >99%) for all types of variations with expected MAF >5%. Furthermore, given the high sensitivity and that false positive may exist in this assay, we confirmed its accuracy of variants with MAF <5% using 35 formalin-fixed and paraffin-embedded (FFPE) tumor specimens by QuantStudio 3D Digital PCR (dPCR; Life Technologies) and obtained a high consistency (32 of 35 mutations detected by NGS were verified). We also used the amplification refractory mutation system (ARMS) to verify the variants with a MAF in a broad range of 2-63% detected in 33 FFPE samples and reached a 100% PPV for this assay. As a potential clinical diagnosis tool, NCP can robustly and comprehensively analyze clinical-related genes with high sensitivity and low cost.
Introduction
Cancer is a genomic disease harboring a cocktail of mutated genes. Personalized medicine approaches based on molecular studies and cytogenetic analysis can treat with therapies directly on mutated cancer driving genes (1) (2) (3) (4) . For example, crizotinib (PF-02341066), a small-molecular inhibitor of the anaplastic lymphoma kinase (ALK), and kinase inhibitor vemurafenib (PLX4032) against BRAF (5-7), both have dramatic effects on most patients with corresponding driver mutations. In fact, hundreds of frequent somatic mutations, which involved in multiple cellular pathways, have been identified in different types of cancer during the past decades (8) , and more comprehensive diagnostic approaches are needed to identify the individual driver mutations which have important impact on tumor progression in different cancer patients (9) and thus, could serve as therapeutic targets in clinical treatment. To assess the status of these biomarkers, several approaches have been implemented in clinical diagnosis, such as fluorescence in situ hybridization (FISH), immunohistochemistry (IHC) and Sanger methodology (10) (11) (12) (13) . However, due to the high cost and technical limitations, it is unaffordable to do the multiplexed assessment of driving somatic alterations.
NGS has already been used to identify hundreds of driving mutations and analyze tens of thousands of tumor samples in a high-throughput with increased performance and decreased costs (14) (15) (16) , which makes it possible to serve as a clinical testing approach. In reality, commercial NGS-based assays have already been developed and validated to provide Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology comprehensive genomic test in clinic (17) (18) (19) (20) . These assays usually have a good performance when detecting variants with high mutant allele frequencies (MAF >10%). However, variants with low MAF usually appear in tumor tissues for many reasons, including contaminating normal cells and intra-tumor heterogeneity (21, 22) . Therefore, it is critical to develop a robust clinical assay that can detect low allele frequency mutations. Here we developed an ultra-high sensitive NGS-based assay, which interrogates all 7011 exons of 483 cancer-related genes and 94 introns of 18 genes with re-arrangement. Using the Illumina HiSeq X platform, hybridization-based capture of target regions reached a high-coverage (>2000X) with acceptable cost. With in-house data analysis approaches, we could identify low MAF (0.5%) variants from sequencing error accurately. We used pools of mixed cell lines with known alterations to perform analytical validation, and 35 FFPe tissue samples to confirm the specificity of low MAF variants detection performance in clinic by dPCR (23) . in addition, ARMS-PCR (24) was used to confirm the overall specificity of our assay.
Materials and methods

NCP NGS design.
Novo assay was developed to characterize SNV/INDEL, CNV and gene fusion in 483 cancer-related genes. These genes were selected based on My Cancer Genome database (https://www.mycancergenome.org), Catalogue of Somatic Mutations in Cancer (COSMIC) and other sources (18, 25) . Briefly, genes containing clinically important variants and genes have been reported as cancer-related were included based on a record of reimbursement in sequencing. All exons of these genes were considered which underwent hybridization-based capture from 483 cancer-related genes (Table I) . For structural rearrangements detection, introns spanning recurrent fusion breakpoints were also included. Agilent's proprietary algorithm and synthetic process was used to generate the baits. The hybrid selection was done using a pool of 120-mer RNA-based baits (Agilent SureSelect) with overlap excess 3-fold for target region. All 47660 hybrid baits for catching target region constitute 2.3 Mb genomic positions, including 7011 exons and 94 introns.
Clinical specimens. Tumor specimens were collected from non-small cell lung cancer (NSCLC) and breast cancer patients at Chinese PLA General Hospital with informed consent according to the internal Review and rules of Ethics. In the very beginning of this assay, clinical samples should match several standards as follows to ensure downstream analysis. At least 10 slices of 5 µm FFPE sections or tissues with a volume of >1 was required. For each sample, hematoxylineosin stained slides ( Fig. 1 ) were prepared and reviewed by a pathologist to estimate tumor purity. All samples with <50% tumor purity were marked for tumor enrichment by microdissection to minimize contamination from normal cells (Fig. 2) .
Cell line sample collection. Normal cell lines harboring the population distribution of known germ line variants were mixed, and multiplexed pools with low MAF variants were used to assess and validate the limit of variant detection. First of all, to get the variants set for assessment, we sequenced 5 cell lines from the 1000 Genomes Project (26) individually and got the SNP and INDEL sites from dbSNP database (build 146) consistent with a homozygous (MAF >90%) or heterozygous (40%<MAF<60%). To estimate the INDEL detection performance, 3 additional cell lines from COSMIC database (http:// cancer.sanger.ac.uk/cancergenome/projects/cosmic/) which also were sequenced individually to get the original MAF of cancer-related somatic variants in each sample. All 8 cell lines were mixed together in designed proportions, and the expected MAF of each variant was calculated on the mixed ratios (Table II) . Eventually, we achieved the 2625 variants spanning a range of expected MAF (0.5-20%) and INDEL lengths (1-40 base pair, bp) as gold-standard (Table III) Table I . Genes and transcripts ID targeted in hybridization capture. Transcripts ID  Gene symbol  Transcripts ID  Gene symbol  Transcripts ID   ABCB1  NM_000927  ETV6  NM_001987  NUP93  NM_001242796  ABCC1  NM_004996  eWSR1  NM_001163287  PAK1  NM_001128620  ABCC2  NM_000392  EZH2  NM_001203248  PAK3  NM_001128173  ABCC4  NM_001105515  FAM46C  NM_017709  PALB2  NM_024675  ABCC6  NM_001079528  FANCA  NM_001018112  PARP1  NM_001618  ABCG2  NM_004827  FANCC  NM_001243744  PARP2  NM_001042618  ABL1  NM_005157  FANCD2  NM_033084  PAX5  NM_001280551  ACVR1B  NM_020327  FANCE  NM_021922  PBRM1  NM_018313  AKT1  NM_005163  FANCF  NM_022725  PDCD1  NM_005018  AKT2  NM_001243027  FANCG  NM_004629  PDGFRA  NM_006206  AKT3  NM_005465  FANCL  NM_001114636  PDGFRB  NM_002609  ALK  NM_004304  FBXW7  NM_001257069  PDK1  NM_002610  AMER1  NM_152424  FCGR3A  NM_001127595  PHF6  NM_032335  APC  NM_000038  FGF10  NM_004465  PHKA2  NM_000292  AR  NM_001011645  FGF14  NM_004115  PIGF  NM_002643  ARAF  NM_001256197  FGF19  NM_005117  PIK3CA  NM_006218  ARFRP1  NM_001267546  FGF23  NM_020638  PIK3CB  NM_001256045  ARID1A  NM_139135  FGF3  NM_005247  PIK3CG  NM_002649  ARID1B  NM_020732  FGF4  NM_002007  PIK3R1  NM_001242466  ARID2  NM_152641  FGF6  NM_020996  PIK3R2  NM_005027  ASXL1  NM_001164603  FGFR1  NM_001174064  PLK1  NM_005030  ATIC  NM_004044  FGFR2  NM_001144919  PPARD  NM_177435  ATM  NM_000051  FGFR3  NM_000142  PPP1R13L  NM_001142502  ATP7A  NM_000052  FGFR4  NM_022963  PPP2R1A  NM_014225  ATR  NM_001184  FGR  NM_001042729  PRDM1  NM_182907  ATRX  NM_000489  FKBP1A  NM_054014  PRDX4  NM_006406  AURKA  NM_198435  FLT1  NM_001160031  PRKAA1  NM_206907  AURKB  NM_001256834  FLT3  NM_004119  PRKAR1A  NM_002734  AXIN1  NM_003502  FLT4  NM_002020  PRKCA  NM_002737  AXL  NM_001278599  FOXL2  NM_023067  PRKCB  NM_002738  B2M  NM_004048  FRK  NM_002031  PRKCE  NM_005400  BAIAP3  NM_001199096  FUBP1  NM_003902  PRKCG  NM_002739  BAP1  NM_004656  FYN  NM_153048  PRKDC  NM_006904  BARD1  NM_000465  FZD7  NM_003507  PRRT2  NM_001256443  BCL2  NM_000657  GALNT14  NM_001253827  PTCH1  NM_001083607  BCL2L2  NM_001199839  GATA1  NM_002049  PTEN  NM_000314  BCL6  NM_001706  GATA2  NM_001145662  PTK2  NM_001199649  BCOR  NM_017745  GATA3  NM_002051  PTK6  NM_001256358  BCORL1  NM_021946  GCK  NM_033508  PTPN11  NM_080601  BCR  NM_004327  GID4  NM_024052  PTPRD  NM_130391  BIRC5  NM_001168  GINS2  NM_016095  RAC2  NM_002872  BLK  NM_001715  GNA11  NM_002067  RAD50  NM_005732  BLM  NM_000057  GNA13  NM_001282425  RAD51  NM_001164270  BRAF  NM_004333  GNAQ  NM_002072  RAF1  NM_002880  BRCA1  NM_007297  GNAS  NM_016592  RARA  NM_001024809  BRCA2  NM_000059  GPC3  NM_001164619  RB1  NM_000321  BRIP1  NM_032043  GPR124  NM_032777  RET  NM_020630  BSG  NM_001728  GRIN2A  NM_001134408  RICTOR  NM_001285440  BTK  NM_000061  GSK3B  NM_001146156  RMDN2  NM_001170793  C11orf30  NM_020193  GSTM1  NM_000561  RNF43  NM_017763  C18orf56  NM_001012716  GSTM3  NM_000849 ROCK1 NM_005406 C8orf34  NM_001195639  GSTP1  NM_000852  ROS1  NM_002944  CAMK2G  NM_001204492  GSTT1  NM_000853  RPL13  NM_033251  CAMKK2  NM_172215  H3F3A  NM_002107  RPS6KA1  NM_001006665  CARD11  NM_032415  HCK  NM_001172132  RPS6KB1  NM_001272044  CASP8  NM_033356  HGF  NM_001010934  RPTOR  NM_001163034  CBFB  NM_001755  HIF1AN  NM_017902  RRM1  NM_001033  CBL  NM_005188  HIST1H3B  NM_003537  RUNX1  NM_001122607  CBR1  NM_001757  HNF1A  NM_000545  SDHA  NM_004168  CBR3  NM_001236  HRAS  NM_005343  SDHAF1  NM_001042631  CCND1  NM_053056  HSP90AA1  NM_005348  SDHAF2  NM_017841  CCND2  NM_001759  IDH1  NM_005896  SDHB  NM_003000  CCND3  NM_001136126  IDH2  NM_002168  SDHC  NM_003001  CCNE1  NM_001238  IGF1  NM_001111285  SDHD  NM_001276506  CCR4  NM_005508  IGF1R  NM_000875  SETD2  NM_014159  CD19  NM_001770  IGF2  NM_000612  SF3B1  NM_001005526  CD22  NM_001185100  IGF2R  NM_000876  SGK1  NM_005627  CD274  NM_001267706  IKBKB  NM_001556  SHH  NM_000193  CD33  NM_001177608  IKBKE  NM_001193322  SIK1  NM_173354  CD38  NM_001775  IKZF1  NM_001220768  SKP2  NM_005983  CD3EAP  NM_012099  IL7R  NM_002185  SLC10A2  NM_000452  CD52  NM_001803  INHBA  NM_002192  SLC15A2  NM_001145998  CD74  NM_004355  INSR  NM_001079817  SLC22A1  NM_153187  CD79A  NM_001783  IRF4  NM_001195286  SLC22A16  NM_033125  CD79B  NM_000626  IRS2  NM_003749  SLC22A2  NM_003058  CDA  NM_001785  ITK  NM_005546  SLC22A6  NM_153277  CDC73  NM_024529  JAK1  NM_002227  SLCO1B1  NM_006446  CDH1  NM_004360  JAK2  NM_004972  SLCO1B3  NM_019844  CDK1  NM_001170407  JAK3  NM_000215  SMAD2  NM_001135937  CDK12  NM_016507  JUN  NM_002228  SMAD4  NM_005359  CDK2  NM_001798  KAT6A  NM_001099413  SMARCA4  NM_001128845  CDK4  NM_000075  KDM5A  NM_001042603  SMARCB1  NM_003073  CDK5  NM_001164410  KDM5C  NM_001146702  SMO  NM_005631  CDK6  NM_001259  KDM6A  NM_021140  SOCS1  NM_003745  CDK7  NM_001799  KDR  NM_002253  SOD2  NM_000636  CDK8  NM_001260  KEAP1  NM_012289  SOX10  NM_006941  CDK9  NM_001261  KIT  NM_000222  SOX2  NM_003106  CDKN1B  NM_004064  KITLG  NM_003994  SOX9  NM_000346  CDKN2A  NM_001195132  KLC3  NM_177417  SPEN  NM_015001  CDKN2B  NM_078487  KLHL6  NM_130446  SPG7  NM_199367  CDKN2C  NM_078626  KMT2A  NM_001197104  SPOP  NM_003563  CEBPA  NM_001285829  KMT2B  NM_014727  SRC  NM_198291  CHEK1  NM_001274  KMT2C  NM_170606  SRD5A2  NM_000348  CHEK2  NM_001257387  KMT2D  NM_003482  SRMS  NM_080823  CHST3  NM_004273  KRAS  NM_033360  STAG2  NM_006603  CIC  NM_015125  LCK  NM_001042771  STAT1  NM_139266  COMT  NM_007310  LIMK1  NM_001204426  STAT2  NM_005419  CREBBP  NM_004380  LMO1  NM_002315  STAT3  NM_003150  CRKL  NM_005207  LRP1B  NM_018557  STAT4  NM_003151  CRLF2  NM_022148  LRP2  NM_004525  STAT5A  NM_003152  CSF1R  NM_005211  LYN  NM_002350  STAT5B  NM_012448  CSK  NM_001127190  MAP2K1  NM_002755 STAT6 NM_001178080 CSNK1A1  NM_001271742  MAP2K2  NM_030662  STEAP1  NM_012449  CTCF  NM_001191022  MAP2K4  NM_003010  STK11  NM_000455  CTLA4  NM_001037631  MAP3K1  NM_005921  STK3  NM_006281  CTNNA1  NM_001903  MAP4K4  NM_145687  STK4  NM_006282  CTNNB1  NM_001904  MAP4K5  NM_198794  SUFU  NM_001178133  CYBA  NM_000101  MAPK1  NM_138957  SULT1A1  NM_177534  CYLD  NM_001042412  MAPK10  NM_138981  SULT1A2  NM_001054  CYP19A1  NM_000103  MAPK14  NM_139013  SULT1C4  NM_006588  CYP1A1  NM_000499  MAPK8  NM_002750  SYK  NM_001174167  CYP1A2  NM_000761  MAPK9  NM_001135044  TCF7L1  NM_031283  CYP1B1  NM_000104  MAPKAPK2  NM_004759  TCF7L2  NM_001198525  CYP2A6  NM_000762  MARK1  NM_001286129  TEK  NM_000459  CYP2B6  NM_000767  MCL1  NM_001197320  TET2  NM_017628  CYP2C19  NM_000769  MDM2  NM_001278462  TGFBR1  NM_004612  CYP2C8  NM_001198853  MDM4  NM_001278516  TGFBR2  NM_003242  CYP2C9  NM_000771  MED12  NM_005120  TK1  NM_003258  CYP2D6  NM_001025161  MEF2B  NM_001145785  TMPRSS2  NM_005656  CYP2E1  NM_000773  MEN1  NM_130803  TNF  NM_000594  CYP3A4  NM_001202855  MERTK  NM_006343  TNFAIP3  NM_006290  CYP3A5  NM_001190484  MET  NM_001127500  TNFRSF10A  NM_003844  CYP4B1  NM_000779  MITF  NM_001184968  TNFRSF10B  NM_003842  DAXX  NM_001254717  MKNK2  NM_199054  TNFRSF14  NM_003820  DDR1  NM_001202523  MLH1  NM_001167617  TNFRSF8  NM_001243  DDR2  NM_001014796  MPL  NM_005373  TNFSF11  NM_003701  DNMT1  NM_001130823  MRE11A  NM_005590  TNFSF13B  NM_001145645  DNMT3A  NM_153759  MS4A1  NM_152866  TNK2  NM_005781  DOT1L  NM_032482  MSH2  NM_000251  TOP1  NM_003286  DPYD  NM_001160301  MSH6  NM_001281494  TP53  NM_001276698  DSCAM  NM_001389  MST1R  NM_001244937  TPMT  NM_000367  E2F1  NM_005225  MTDH  NM_178812  TPX2  NM_012112  EGF  NM_001178131  MTHFR  NM_005957  TSC1  NM_001162426  EGFL7  NM_201446  MTOR  NM_004958  TSC2  NM_000548  EGFR  NM_201283  MTRR  NM_002454  TSHR  NM_001018036  EGR1  NM_001964  MUTYH  NM_001048174  TYMS  NM_001071  EMC8  NM_001142288  MYC  NM_002467  TYRO3  NM_006293  EML4  NM_019063  MYCL  NM_005376  U2AF1  NM_001025204  ENOSF1  NM_001126123  MYCN  NM_005378  UBE2I  NM_194259  EP300  NM_001429  MYD88  NM_001172566  UGT1A1  NM_000463  EPHA1  NM_005232  NAT1  NM_001160174  UGT1A9  NM_021027  EPHA2  NM_004431  NAT2  NM_000015  UGT2B15  NM_001076  EPHA3  NM_182644  NCAM1  NM_001076682  UGT2B17  NM_001077  EPHA4  NM_004438  NCF4  NM_013416  UGT2B7  NM_001074  EPHA5  NM_001281767  NCOA3  NM_001174088  UMPS  NM_000373  EPHA7  NM_004440  NCOR1  NM_001190438  VEGFA  NM_001171627  EPHA8  NM_001006943  NEK11  NM_145910  VEGFB  NM_003377  EPHB1  NM_004441  NF1  NM_001128147  VHL  NM_000551  ePHB2  NM_004442  NF2  NM_181830  Wee1  NM_001143976  ePHB3  NM_004443  NFe2L2  NM_001145413  WiSP3  NM_198239  ePHX1  NM_000120  NFKBiA  NM_020529  WNK3  NM_020922  eRBB2  NM_004448  NKX2-1  NM_003317  WT1  NM_001198552  ERBB3  NM_001005915  NOS3  NM_001160111  XPC  NM_001145769 culture flasks at a concentration of 1x10 5 viable cells/ml and incubated at 37˚C in a humidified atmosphere containing 5% CO 2 .
Gene symbol
Library preparation and sequencing. Generally, genome DNA extracted was performed using DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany). For FFPE sample special, DNA was isolated using the GeneRead DNA FFPE kit (Qiagen, Valencia, CA, USA) following the protocol. Besides the purification of high yields of DNA from FFPe tissue sections, this kit could remove deaminated cytosine to prevent false results in sequencing (27) . The ratio of absorbance at 260 and 280 nm is used to assess the purity of extracted DNA, and we used the Qubit ® Quantitation Platform to quantitated DNA. A Covaris S220 focused-ultrasonicator (Covaris, Woburn, MA, USA) Transcripts ID   ERBB4  NM_005235  NOTCH1  NM_017617  XPO1  NM_003400  ERCC1  NM_202001  NOTCH2  NM_001200001  XRCC1  NM_006297  ERCC2  NM_001130867  NPM1  NM_001037738  XRCC4  NM_022406  ERG  NM_001136155  NQO1  NM_000903  YES1  NM_005433  ESR1  NM_000125  NRAS  NM_002524  ZAP70  NM_207519  ETV1  NM_001163151  NTRK1  NM_002529  ZC3HAV1  NM_024625  ETV4  NM_001261439  NTRK2  NM_001007097  ZNF217  NM_006526  ETV5  NM_004454  NTRK3  NM_001007156  ZNF703  NM_025069 Genes targeted for rearrangement detection
Gene symbol Transcripts ID Gene symbol Transcripts ID Gene symbol Transcripts ID
The genes and transcripts by the Novogene Comprehensive Panel. This assay covers all exons and introns spanning recurrent fusion breakpoints in v64 of the COSMIC database. In order to get more gold-standard variants with mutant allele frequencies from 0.5 to 20%, cell lines were mixed in designed proportions. Mixed cell lines contained gold-standard variants with mutant allele frequencies ranging from 0.5 to 20%. These variants were used to calculate the detection performance of our assay.
was used to fragment genomic DNA (500 ng) and an Agilent Bioanalyzer 2100 (Agilent Technologies) to ensure an average fragment size of 200 to 400 base pair (bp). The library preparation after fragmentation were done using instruction manual of KAPA Hyper Prep kit. The protocol included: i) repairing the DNA ends; ii) adding 'A' base to the DNA fragments; iii) ligating the paired-end adaptor; iv) purifying the sample using AMPure XP beads; and v) amplifying the adaptor-ligated library and purifying the sample using AMPure XP beads. Prepared library was hybridized using NCP custom designed baits as described in SureSelectQXT (Agilent Technologies) and the product was then amplified for 14 PCR cycles. The size range of the prepared library was assessed using Agilent 2100 Bioanalyzer and qualified using ABi SteponePlus. The concentration of each library was quantified using qPCR NGS Library Quantification kit and Protocol was used to calculate the final pooling volume to sequencing. The products were sequenced using the Illumina HiSeq X platform with pairedend sequencing runs (2x150) under Illumnina recommended protocols.
Data analysis. Clean data were generated by data processing steps including base calling, demultiplexing and adapter trimming. All these steps were performed using Illumina HiSeq X vendor software on default parameters. We further performed our in-house software for clean data quality control (QC) which included: i) removing read pairs if any one of the two reads containing base 'N' >10%; ii) removing read pairs if any one of the two reads containing base with quality below Q10 >50%; iii) trimming the 3' end of the read from the first base below Q20; and iv) removing reads shorter than 100 bp. Clean data after QC were mapped to the human reference genome (GRCh37) using BWA aligner v0.7.8 (28) with the default parameters. PCR duplicate read removal was done using Picard 1.119 (http://picard.sourceforge.net/index.html). According to the result, a sequence metric collection was generated including the number of total reads, percentage of reads mapped, on target reads number, average target coverage and percentage of target region with >200X and 1000X coverage. Before SNV and INDEL calling, local realignment was performed using Genome Analysis Toolkit (GATK version 2.7-2-g6bda569) (29, 30) with default parameters and recommended 'known sites' in GATK best practice (https://software.broadinstitute. org/gatk/best-practices/). For SNV detection, we denote the reference allele and the coverage of each site as r and d and denote the error rate corresponding to the base calling at read i (i = 1…d) as e i . We used a null model to explain the data in which there is no SNV at that site and all non-reference alleles to be sequencing error. The number of variant bases (k) with e i <1e -3 (associated Phred-like quality score q i >30) in each site was then given a binomial distribution. The probability under this null model was given by the following formula:
where P(X = i|d) was the probability of observing i variants in the d reads of the site. Assuming the sequencing errors were independent across reads and occurred with probability e 0 (e 0 = 1e -3 /3) to each non-reference allele. We could obtain The P-value was then given by P(X≥k|d) and the cut-off (P-value <1e -6 ) was established to eliminate random sequencing error. For INDEL detection, we simply kept variants supporting reads >10. We also employed several filters to reduce systematic errors. empirical filters including strand bias (Fisher's exact test, P<1e -6 ), site median base quality (MBQ >30), site median mapping quality (MMQ >30), variant MAF (MAF >0.5%). Variants pass filters were annotated by dbSNP b146, My Cancer Genome database (https://www.mycancergenome. org) and Oncomine database v1.4.1 to get the clinical relevant information. However, cross library contamination may occur and a report would not be generated once the sample contained >10 variants with low-MAF (MAF ≤10%) in dbSNP. in the report stage, all annotated variants with MAF ≥5% would be reported and other cancer-related variants would be validated by 3dPCR. The whole workflow for the data analysis is outlined in Fig. 3 . The parameters and descriptions used are listed in Table IV . Compared with other software. To measure the effect of our approach, we compared the pooled cell-line result with GATK, a widely used software. We followed the 'GATK best practice', the 'IndelRealigner' parameter 'LOD_ Threshold_For_Cleaning' was 0.3, the 'BaseRecalibrator' was with default parameters, the SNV/INDEL calling type was 'HaplotypeCaller' with parameters 'standard_min_confidence_threshold_for_emitting' as 10 and 'standard_min_confidence_threshold_for_calling' as 30.
Performance statistics calculation. For sensitivity estimation, variants detected in pools would be assigned as true positive (TP), or false negative (FN) if not detected. Sensitivity was calculated as TP/(TP+FN). For specificity estimation, the pool variants also detected in the pure sample were assigned as true positive (TP), or false positive (FP) if none was detected. PPV was calculated as TP/(TP+FP).
Mutation detection by dPCR. dPCR is a method used in absolute quantification analysis of clonally amplified nucleic acids (including DNA, cDNA, methylated DNA or RNA). With dPCR, a sample is partitioned so that individual nucleic acid molecules within the sample are localized and concentrated within many separate regions. After PCR amplification, nucleic acids may be quantified by counting the regions that contain PCR end-product, positive reactions. Here, we used the QuantStudio™ 3D Digital PCR System platform (Life Technologies) regarding SNP mutation quantitation.
For dPCR, the first step is preparing and loading samples onto QuantStudio™ 3D Digital PCR 20K chips. Mutations were analysed by TaqMan ® SNP Genotyping Assays (Life Technologies), which containing TaqMan ® -MGB probes and primers. We prepared 15 µl reaction mixes according to the manufacturer's instructions, and loaded 14.5 µl onto each chip. The Mix contains ROX ® dye, which served as a passive reference. After chips were loaded, we run the Digital PCR 20K Chips with a ProFlex™ 2x Flat PCR System under the following conditions: 96˚C for 10 min, 39 cycles at 56˚C for 2 min and at 98˚C for 30 sec, followed by a final extension step at 56˚C for 2 min. After thermo-cycling, we analyzed the prepared chips using dPCR instrument.
Mutation detection by ARMS-PCR.
ARMS-PCR is a realtime PCR-based test which covers the 29 EGFR hotspots from exon 18-21. The assay was performed according to the manufacturer's protocol for the ADx EGFR29 Mutation kit (Amoy Diagnostics, Co., Ltd., Xiamen, China) with the MX3000P (Stratagene, La Jolla, CA, USA) real-time PCR system. Template DNA (0.4 µl), 3.6 µl deionized water and 16 µl other reaction components was used in the RT-PCR reaction system. PCR was performed with initial denaturation at 95˚C for 10 min, followed by 40 cycles of amplification (at 95˚C for 30 sec and 61˚C for 1 min). The results were analyzed according to the criteria defined by the manufacturer's instructions. Positive results were defined as [Ct(sample) -Ct(control)] < Ct(cut-off). 
Data analysis Description and thresholds
Quality control Remove read pairs with low quality, which may lead to false positive in downstream process. Four tests are used to identify such read pairs: i) read pair with one of the two reads containing base 'N' >10%; ii) read pairs with any one of the two reads containing base with quality below Q10 >50%; iii) trimming the 3' end of the read from the first base below Q20; and iv) removing reads <100 bp.
Mapping
Reads are mapped to human reference using BWA aligner v0.7.8 with BWA-MeM algorithm and relevant default parameters.
Realignment
The GATK realignment is used to correct the misalignment due to the presence of an INDEL. This step use two files 'Mills_and_1000G_gold_standard.indels.b37.sites.vcf' and '1000G_phase1.indels.b37.vcf' (https://software.broadinstitute.org/gatk/best-practices/) to get these INDEL. The default parameters are used to perform the realignment.
Call SNV A binomial test is used to separate true positive from noises. The P-value cut-off is 1e -6 , and the probability of sequencing error is 1e -3 /3.
Call INDEL A cut-off of 10 support reads is used to call INDEL.
Hard filter
To further remove false positives, several hard filters have been used as follows: i) Fisher's exact test for strand bias, P-value <1e -6 . Some false positives are generated in sequencing step and have close relationship to the front of the sequence (homopolymer or other special sequence); ii) site median base quality >30. In case of the base quality of each read could not represent the true error rate, the median base quality of each site is used to evaluate such error rate; iii) site median mapping quality >30. This filter is used to avoid the misalignment of repeat sequences with small difference in human reference which are easily mistaken as SNV.
These filters were obtained from clinical samples and covered all special cases that we had met before. Therefore, it could identify true positive variants from most noise in sequencing.
Results
Overview. NCP is a NGS-based clinical test for detection of somatic cancer related mutations. DNA was extracted from tumor tissues and FFPE samples, 500 ng of which was fragmented, captured using custom-designed hybridization-based biotinylated cRNA reagents and amplified via limited-cycle PCR to enrich 7,011 exons and 94 introns of 483 cancer related genes (totaling ~2.3 million sites). We used clinical samples to generate the bioinformatics pipeline for data analysis (Table IV) and cell lines to validate the whole work flow. For the 8 single cell lines, using the Illumina HiSeq X platform, achieving an average of 13,330 Mb (SD=3,995 Mb) total bases with 38.09% on-target (SD=4.78%), target regions were sequenced to 2148X (SD=537X) median coverage across targeted bases, with 99.05% (SD=0.28%) of targeted bases covered by at least 200 reads (Table V) . The 2453 SNV and 172 INDEL detected in single cell line consistent with database would be used for assessment of SNV/INDEL detection. Pools of mixed cell lines were used to get the relationship between median coverage and performance, which achieved total bases of 4,762, 10,896 and 16,351 Mb, the median coverage of 1,029X, 2,237X and 3,194X (Table VI) . Due to the high sensitivity NGS benefit from high coverage, the hotspot mutations with MAF <5% detected by this assay in 35 FFPE samples were confirmed by dPCR. All samples used in this test are summarized in Table VII . Finally, 33 hotspot mutations detected by NGS in FFPE samples with a MAF from 2 to 63% in NGS were tested by ARMS-PCR.
SNV detection performance. SNV detection was performed using a Binomial methodology allowing the detection of low MAF somatic mutations across the 2.3 Mb assayed with high sensitivity. For the mixed cell line pools, overall SNV detection performance was high, the results of different depth are shown in Table VIII , for an average depth of 2237, 100% (95% CI, 95.1-100%) of SNV at MAF >10% were successfully detected, as well as 99% (95% CI, 98.6-100%) of SNV at MAF 5-10%. The detection of SNV with MAF between 0.5-5% performance was 92.2% (95% CI, 90.7-93.5%) (Fig. 4A and C and  Table VIIIA ). In addition, high sensitivity was accompanied with good PPV (the fraction of SNV calls in the pools can also be detected in any of the individual cell lines; Table VIIIB) 99.2% (95% CI, 99-99.4%). The false positives may be due to variants with such a low MAF (<5%) no difference with sequencing noise could hardly be identified. A dPCR confirmation for cancer-related SNV with MAF <5% reported by NGS is necessary before reporting.
INDEL detection performance.
For INDEL detection, we simply discarded the variants supporting less than 10 reads. The results of different depth are shown in Table IX positive under 10%, a dPCR confirmation of these cancerrelated INDEL with MAF <10% before reporting is needed.
Comparison with other bioinformatics approaches. We evaluated the performance of our bioinformatics pipeline with the cell line models above, focusing on two key steps of our approach. First, we applied statistical models that allow for the identification of a mutation at low MAF from random errors in Illumina sequencing. Second, we used priori knowledge to identify systematic errors always accompanied with specific characteristics, such as strand bias and low base/ mapping quality. To measure the effect of our approach, we compared the pooled cell-line result with GATK -widely used software. The GATK detection sensitivity of SNV with MAF >10% was 64.38% (95% CI, 52.3-75.3%), and SNV with 5%<MAF<10% was under 10% but the PPV was 100% (95% CI, 99.7-100%). The sensitivity of INDEL with MAF >10% was 67% (95% CI, 9.4-99.2%), and a high PPV 100% (95% CI, 99-100%) (Tables X and XI) , possibly because this widely used tool is designed for whole-genome or wholeexon sequencing data with relatively low depth and variants with high allele frequency, which underline that appropriate The SNV detection performance of our pipeline in analytical validation. False negatives were germ line SNPs in constituent cell lines that were not detected in mixed cell line data. False positives were SNV calls in pooled samples absent from pure cell lines. MAF, mutation allele frequency; FN, false negative; SeN, sensitivity; Ci, confidence interval (calculated as the exact 95% binomial confidence interval). filters for ultra-deep sequencing data analysis were critical. Actually, compared with slight performance upgrades under increased coverage depth, the effect of appropriate filters was remarkable in this test. B, Summary of small insert and deletion detection performance (specificity) The INDEL detection performance of our pipeline. INDEL calls in pooled samples had the same base composition and position (±25 bp) which were considered to be true positives. False positives were INDEL calls in pooled samples that were absent from pure cell lines. MAF, mutation allele frequency; FN, false negative; SeN, sensitivity; Ci, confidence interval (calculated as the exact 95% binomial confidence interval). Concordance between NGS and other approaches. The above studies demonstrate that the NGS-based test has the performance characteristics necessary to accurately detect SNV and iNDeL. We further validated test accuracy by Table X . Summary of SNV detection performance by GATK (sensitivity, ppv).
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------coverage FN SEN (%) CI (%) FN SEN (%) CI (%) FN SEN (%) CI (%) FN SEN (%) CI (%)
PPV -------------------------------------------------------------------------------------------------------------------------
A, Summary of SNV detection performance by GATK (sensitivity) The SNV detection performance of GATK pipeline in mixed cell lines. False negatives were germ line SNPs in constituent cell lines that were not detected in mixed cell line data. False positives were SNV calls in pooled samples that were absent from pure cell lines. Ci, confidence intervals (calculated as the exact 95% binomial confidence interval); MAF, mutation allele frequency. FN, false negative; SeN, sensitivity. (Tables XII and  XIII) . Three variants were present at <3% MAF in NGS that were not detected by dPCR. The detected MAF of the two technologies is shown in Fig. 5 . Finally, we random selected 33 FFPE samples (NSCLC) with hotspot mutations and performed the ARMS-PCR to verify the overall PPV of our assay. As a result, all 33 mutations could be detected by ARMS-PCR and the PPV was 100% (95% CI, 89.42-100%; Table XIV ).
Discussion
Cancer diagnostic is undergoing a rapid development (31) (36, 37) , make it critical to generate a complex validation of NGS assay.
In the present study, we developed and validated the NGS-based assay, using germ line mutations in 1000 genome cell lines and certain somatic INDEL in cosmic database to simulate the tumor heterogeneity or impurity in clinical samples. We mixed these samples to measure the analytic sensitivity and PPV of NCP assay at low MAF and used 3 pools to obtain the correlation between median coverage and variants detection performance. The performance of our test was high for variants with MAF >5%. In cell line model with 2236X median coverage, sensitivity was 99.8% for SNP, 94.7% for INDEL with a PPV of 99 and 98%. The 0.5%<MAF<5% variant sensitivity was 92.2% for SNV and 91.5% for INDEL which was not desirable. Because of the complexity of 483 genes, it was difficult to ensure such low MAF variant detection sensitivity. On the other hand, we confirmed the low MAF detection by dPCR which could identify rare mutations specifically. We also compared our bioinformatics pipeline with common pipeline GATK (29, 30) , which is widely used in genotype analysis. The overall PPV was high at the expense of sensitivity, which may be due to these approaches being developed to call germ line variants. The results highlighted that appropriate filtering approach is critical for low MAF variant detection. Actually, the filters were more important than the increase of coverage depth as showed in the different coverage tests. For specificity analysis, each called variant was classified as a false positive if a matching alteration was not detected in the pure sample. However, this approach could not recognize the false positive generated by systematic errors. Given the high sensitivity of this technology, high-throughput clinical trials are required to confirm its reliability for the molecular diagnosis of cancer (38) . Therefore, 35 patient specimens previously tested by NCP assay and having low MAF <5% variants were used to test in parallel by dPCR. The correlation coefficient of NGS and dPCR was low (0.78) and 32 of 35 (91.43%) NGS detected variants could be confirmed by dPCR. The discordance was possibly due to the heterogeneity in tumor specimens or false positive in NGS, the dPCR verification is needed for such low MAF variants before reporting. Like low The concordance between NGS and 3D digital PCR for variants with mutant allele frequency under 5%.
MAF variants, we used ARMS-PCR to test the 33 random selected FFPE samples with hotspot mutations detected by NGS and obtained a high concordance (PPV=100%). Taken together, we used high sequencing coverage and a statistical test with several hard filters generated from clinical samples to separate low MAF SNV/INDEL from false positives. To balance the cost of NGS and accuracy of variant calls for low MAF variants, we used pooled cell line models with certain germ line SNP in different data size to get the relationship accuracy between data size and variants. From this test, we validated the best target median coverage (2000X) that can meet the analysis requirement, whereas the low MAF variants detection needed to be corrected by dPCR. On the other hand, the overall performance of this assay was good in the ARMS-PCR test. However, our results cannot meet the requirement of different variant types in clinical use like other NGS-based approaches (17) (18) (19) (20) 39) , which is one of the most important aspects for NGS compared to other traditional approaches. Furthermore, due to the DNA requirement of dPCR verification and quantity of extraction in plasma (40,41), The mutant allele frequency of each variant detected in NGS and 3D Digital PCR. dPCR, 3D Digital PCR; NSCLC, non-small cell lung cancer are shown.
this NGS-dPCR combined approach could only be used in FFPe sample but not plasma. With the advantages of noninvasive and overcome tumor-heterogeneity (42) (43) (44) , the sequencing of plasma sample still needed more study. To reduce the sequencing errors confound with rare mutations, a NGS method termed Duplex sequencing was developed these years and may be useful in future plasma sequencing (45) (46) (47) . In addition, given the capability of NGS test to detect variants with low MAF, the correlation between the NGS clinical report and the effect of targeted therapy still need further assessment (48) . Finally, our NCP assay can give more mutation information and thus expand the treatment choices for patients, but more efforts still need to be done for future cancer diagnostics. The specificity of our assay in clinical samples. Τhirty-three randomly selected FFPe tissues with positive detection in NGS were tested by ARMS-PCR. The ΔCt was the Ct value of sample minus control and the cut-off for T790M, L858R, L861Q, 19-Del were 8, 11, 12, 11, respectively. ΔCt, Ct (sample) -Ct (control). NSCLC, non-small cell lung cancer.
